Loading...
Loading...
IMPL| Name | Value |
|---|---|
| Revenues | 5.0M |
| Cost of Revenue | 2.2M |
| Gross Profit | 2.8M |
| Operating Expense | 15.6M |
| Operating I/L | -12.8M |
| Other Income/Expense | -1.0M |
| Interest Income | 0.0M |
| Pretax | -13.8M |
| Income Tax Expense | -0.6M |
| Net Income/Loss | -13.8M |
Impel Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of therapies for central nervous system diseases in the United States. Its lead product candidate, Trudhesa, is an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder, and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease.
